Amazon's Project Kuiper (Leo) has surpassed 390 satellites in orbit after its latest Atlas V launch, bringing the total to 396. This milestone positions Amazon to begin initial internet service this year, despite challenges with grounded rockets from Blue Origin and ULA. The company aims for broader coverage with over 3,200 satellites to compete with SpaceX's Starlink, and has already secured partnerships with companies like Delta Air Lines.

Delta Air Lines has issued a warning to passengers about potential aircraft performance constraints at LaGuardia Airport (LGA) due to an extreme heat advisory. The high temperatures can affect aircraft take-off capabilities, leading the airline to offer flexible rebooking options for flights to, from, or through LGA until July 4, 2026. Despite these concerns, Delta experienced fewer delays and cancellations compared to its competitors on July 2.

Y Intercept Hong Kong Ltd has made a significant new investment in Royal Caribbean Cruises Ltd. by acquiring 52,956 shares valued at $14.6 million during the first quarter. This investment follows Royal Caribbean's stronger-than-expected quarterly results, with the company raising its guidance for both Q2 and full-year 2026. Despite a "Moderate Buy" consensus from analysts, some concerns linger regarding potential softer bookings and broader industry risks, although analyst sentiment remains generally positive with an average price target of $345.58.

Altria has increased its quarterly dividend by 4% to $1.06 per share, marking the 60th increase in 56 years. This increase follows a 5.3% year-over-year jump in Q1 2026 revenue, driven by pricing power in smokeable products despite volume declines. TIKR's mid-case model targets an $86 price for Altria stock, projecting an 18.9% total return by 2030, largely due to the dividend yield.

Delta Air Lines stock is currently reflecting a thin news day, with investor focus remaining on the airline's core operations, pricing strategies, and overall travel demand. The article highlights Delta's business model, which emphasizes premium cabins, loyalty revenue, and cargo, making schedule reliability and load factors crucial for earnings. While details on specific live catalysts are limited, the stock's performance is tied to macro travel trends, capacity discipline, and fuel costs, with its defensive reputation stemming from its blend of offerings.

Essex Property Trust, a REIT specializing in West Coast multifamily properties, continues to expand its portfolio in high-demand coastal markets. The company's strategy focuses on generating recurring rental income from professionally managed apartment communities, balancing occupancy with competitive rental rates. Investors are keenly observing how rental trends and interest rates will influence its returns in the US multifamily housing market.

Henry Schein Inc (SCHE) serves as a major distributor of healthcare products and services, primarily for dental, medical, and animal health practitioners. The company differentiates itself through traditional distribution channels combined with practice-management software and value-added services, enhancing customer relationships and generating recurring revenue. Its extensive product portfolio, technology solutions, and comprehensive support services solidify its position in the North American healthcare market.

NextEra Energy Inc is a prominent US power and renewables company known for its blend of regulated utility operations and renewable energy assets. The article explores how the company balances stable, dividend-paying utility services with significant investments in clean energy infrastructure, including wind, solar, and battery storage. It highlights NextEra's growth strategy, capital investment plans, regulatory relationships, and its role in the energy transition, emphasizing the hybrid model that attracts investors seeking both income and growth.

Esperion Therapeutics, a biopharmaceutical company, centers its strategy on developing oral non-statin cholesterol therapies for patients who cannot tolerate statins or need additional lipid-lowering support. The company aims to differentiate itself by offering an oral alternative in a market dominated by statins and injectable therapies, focusing on treatments that reduce LDL-C and cardiovascular events. Investors are watching the company's ability to secure regulatory approvals, navigate market competition, and expand patient adoption, with stock performance reflecting its success in translating scientific expertise into commercial traction.

Brown & Brown (ISIN US1156371007) stock remains stable, driven by its diversified brokerage and risk-management model. The company's focus is on recurring commissions, client retention, and integrating acquisitions, rather than underwriting risks directly. Investors prioritize consistent cash generation through its retail, wholesale, and specialty programs.